Availability of a matched sibling donor in donor versus no donor trials
| Trial . | Total . | Sibling donor . | Sibling no donor . | No siblings . | Not known if siblings, no donor . | All no donor . |
|---|---|---|---|---|---|---|
| MRC UKALLXA21 | 134 | 47 (35%) | 68 (51%) | 19 (14%) | 87 (65%) | |
| PMH 9223 | 70 | 34 (49%) | 23 (33%) | 13 (19%) | 36 (51%) | |
| JALSG-ALL9324 | 129 | 32 (25%) | 97 (75%) | 97 (75%) | ||
| GRAALL 200325 | 132 | 44 (33%) | 88 (67%) | 88 (67%) | ||
| HOVON 18 ALL27 | 94 | 36 (38%) | 52 (55%) | 6 (6%) | 58 (62%) | |
| GOELAL0228 | 128 | 33 (26%) | 95 (74%) | 95 (74%) | ||
| NILG ALL08/9629 | 45 | 18 (40%) | 27 (60%) | 27 (60%) | ||
| HOVON 37 ALL27 | 160 | 54 (34%) | 84 (53%) | 22 (14%) | 106 (66%) | |
| EORTC 0686111 | 220 | 67 (30%) | 118 (54%) | 34 (15%) | 1 (0%) | 153 (70%) |
| UKALLXII/E299314 | 1193 | 453 (38%) | 614 (51%) | 126 (11%) | 740 (62%) | |
| PETHEMA ALL-9315 | 154 | 70 (45%) | 84 (55%) | 84 (55%) | ||
| LALA-9416 | 290 | 116 (40%) | 118 (41%) | 43 (15%) | 13 (4%) | 174 (60%) |
| EORTC ALL-4/0695117 | 213 | 93 (44%) | 95 (45%) | 25 (12%) | 120 (56%) |
| Trial . | Total . | Sibling donor . | Sibling no donor . | No siblings . | Not known if siblings, no donor . | All no donor . |
|---|---|---|---|---|---|---|
| MRC UKALLXA21 | 134 | 47 (35%) | 68 (51%) | 19 (14%) | 87 (65%) | |
| PMH 9223 | 70 | 34 (49%) | 23 (33%) | 13 (19%) | 36 (51%) | |
| JALSG-ALL9324 | 129 | 32 (25%) | 97 (75%) | 97 (75%) | ||
| GRAALL 200325 | 132 | 44 (33%) | 88 (67%) | 88 (67%) | ||
| HOVON 18 ALL27 | 94 | 36 (38%) | 52 (55%) | 6 (6%) | 58 (62%) | |
| GOELAL0228 | 128 | 33 (26%) | 95 (74%) | 95 (74%) | ||
| NILG ALL08/9629 | 45 | 18 (40%) | 27 (60%) | 27 (60%) | ||
| HOVON 37 ALL27 | 160 | 54 (34%) | 84 (53%) | 22 (14%) | 106 (66%) | |
| EORTC 0686111 | 220 | 67 (30%) | 118 (54%) | 34 (15%) | 1 (0%) | 153 (70%) |
| UKALLXII/E299314 | 1193 | 453 (38%) | 614 (51%) | 126 (11%) | 740 (62%) | |
| PETHEMA ALL-9315 | 154 | 70 (45%) | 84 (55%) | 84 (55%) | ||
| LALA-9416 | 290 | 116 (40%) | 118 (41%) | 43 (15%) | 13 (4%) | 174 (60%) |
| EORTC ALL-4/0695117 | 213 | 93 (44%) | 95 (45%) | 25 (12%) | 120 (56%) |
Ph+ patients have been excluded.